http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200128394-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e473613f549ad747f3af840e73fac8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-95 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 2019-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b09d60e96f4bb0cd04e4577099a5911 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5634c9b0a1a6f53ca0562f37bfcb345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e1479931dc28b3ed5a432a80892c123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3d23151800b68618f62c5ea2a985d6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c61c21e504486be66539a77506358aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_711011a93016927067bf17edc4942536 |
| publicationDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200128394-A |
| titleOfInvention | 2,4-diaminoquinazoline derivative and medical use thereof |
| abstract | This application has the following formula I: [Formula I] Quinazoline derivatives, pharmaceutical compositions comprising a compound of formula I, and the use of a compound of formula I in the treatment or prevention of viral infections, virus-induced diseases, cancer or allergies. In formula I, R 1 is C 3-8 optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C 1-3 alkyl, or C 1-3 alkoxy. Alkyl, the carbon of R 1 bonded to the amine at the 4-position of the quinazoline is present in the (R)-configuration, and R 2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoro Methyl, or carboxylic acid amide, wherein each methyl, methoxy and cyclopropyl is optionally substituted with one or more substituents independently selected from fluorine and nitrile, R 3 is hydrogen or deuterium, R 4 Is hydrogen, deuterium, fluorine, methyl, carboxylic acid ester, carboxylic acid amide, nitrile, cyclopropyl, C 4-7 heterocyclic, or 5-membered heteroaryl group (wherein each of methyl, cyclopropyl, C 4- 7 heterocyclic and 5-membered heteroaryl groups are optionally substituted with one or more substituents independently selected from fluorine, hydroxyl or methyl), and R 5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, However, at least one of R 2 , R 3 , R 4 and R 5 is not hydrogen. |
| priorityDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.